Zhifei Biological and Merck Sign Revised Agreement to Enhance Strategic CooperationCoinLive·Apr 2 at 06:55 AMXBI+2.40%SBIO+3.26%
ZHIFEI-BIOL: The improved Ankara strain vaccinia virus (MVA) monkeypox live attenuated vaccine has received clinical trial approval notificationWallstreetcn·Mar 16 at 03:33 AM300122+2.14%
ZHIFEI-BIOL: The recombinant varicella-zoster virus ZFA01 adjuvanted vaccine (CHO cells) has received the clinical trial approval noticeWallstreetcn·Feb 9 at 02:09 AM300122+2.14%
ZHIFEI-BIOL expects a net loss attributable to shareholders of the listed company of RMB 10.6979361 billion to RMB 13.7256538 billion in 2025, compared to a profit of RMB 2.0184785 billion in the previous yearWallstreetcn·Jan 12 at 04:44 PM300122+2.14%
ZHIFEI-BIOL: CA111 injection has entered Phase I clinical trialsWallstreetcn·Jan 12 at 04:35 AM300122+2.14%
ZHIFEI-BIOL released its performance for the first three quarters, with a net loss attributable to the parent company of 1.206 billion yuanZhitong·Oct 29, 2025 at 05:01 PM300122+2.14%
ZHIFEI-BIOL: The company's self-developed influenza virus split vaccine has obtained a drug registration certificateZhitong·Sep 29, 2025 at 06:36 AM300122+2.14%
ZHIFEI-BIOL: CA111 injection has received approval for clinical trialsZhitong·Sep 17, 2025 at 04:43 AM300122+2.14%
A-share innovative drug concept stocks fluctuated upward, EASTON BIOPHARMACEUTICALS and BioKangtai rose over 10%, Thalys, Staidson BioPharm, ALK, and ZHIFEI-BIOL followed suitZhitong·Aug 24, 2025 at 08:41 PM300122+2.14%688513-4.44%
ZHIFEI-BIOL: The company's application for clinical trials of the acellular DTP (component) combined vaccine (for adults and adolescents) has been acceptedWallstreetcn·Aug 18, 2025 at 06:14 AM300122+2.14%
ZHIFEI-BIOL: Net loss of 597 million yuan in the first half of 2025Zhitong·Aug 18, 2025 at 05:58 AM300122+2.14%
ZHIFEI-BIOL: Its quadrivalent influenza vaccine has completed the first nationwide vaccinationZhitong·Aug 13, 2025 at 01:53 AM300122+2.14%
Goldman Sachs focuses on "wealthy elderly individuals," brain-computer interfaces, and gene drugs are the future of high-end self-paid medical care in ChinaWallstreetcn·Jul 28, 2025 at 10:52 PM300122+2.14%688050+2.98%
